Patients

Patients with biochemical recurrence of PCa after treatment with curative intent (RP, EBRT, high intensity focused ultrasounds—HIFU or brachytherapy) were prospectively included in the ICHOROPRO study (Eudract 2007-004419-69).

The main inclusion criteria were as follows: PSA serum level >2ng/mL or >1ng/mL with a doubling time <3 months or >0.5ng/mL with a Gleason score ≥7 and a doubling time <6 months. PSA serum level was determined within 3 months before FCH PET/CT. The results of conventional imaging modalities, at least recent pelvis MRI and BS, must have been negative or equivocal.

The exclusion criteria were: radiotherapy within 4 months, other known active malignancy or inflammatory disorder and any change in PCa treatment that occurred after the last MRI, BS or serum PSA assay.